KEYNOTE-024, PDL-1 TPS ≥ 50% advanced NSCLC
KEYNOTE-010, PDL-1 TPS ≥ 1% advanced NSCLC
29.5%
22.1%
12.3 %
3-year OS Rates
Herbst RS, ASCO 2017
Brahmer, ASCO 2017
PDL1 expression: validated as biomarker in NSCLC prospective clinical trials